

Human LILRB1(ILT2) Protein; His Tag(Q8NHL6-1)

Product Information


Product Name	Human LILRB1(ILT2) Protein; His Tag(Q8NHL6-1)
Storage temp	Store at $\leq -70^{\circ}\text{C}$, stable for 6 months after receipt. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Catalog# / Size	GM-88549RP-100 / 100 μg GM-88549RP-1000 / 1 mg

Protein Information

Alternative Names	CD85J,LILRB1,CD85,ILT2,LIR1,MIR7
Source	Human LILRB1(ILT2) Protein; His Tag(Q8NHL6-1) (GM-88549RP) is expressed from human 293 cells (HEK-293). It contains AA Ala 23 - Thr 431 (Accession # Q8NHL6-1). This protein carries a His tag at the C-terminus.
Purity	> 95% as determined by SDS-PAGE
Endotoxin	< 1 EU/ μg , determined by LAL gel clotting assay
Predicted Mol Mass	45.4 kDa
Formulation	Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4.
Description	LILRB1 protein, full name Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1, is an important cell surface receptor protein and a member of the immunoglobulin-like receptor family. LILRB1 protein plays a crucial role in regulating immune responses in various immune cells, including monocytes, dendritic cells, and natural killer (NK) cells. Abnormal expression of LILRB1 protein is closely associated with the occurrence and development of various malignant tumors and immune-related diseases, particularly leukemia, lymphoma, and certain solid tumors. Currently, LILRB1 is emerging as a promising target for immunotherapy. Several LILRB1-blocking antibodies, such as BND-22 (Biond Therapeutics), are under preclinical or early clinical investigation. These agents can restore anti-tumor immune responses by blocking the inhibitory signaling pathways mediated by LILRB1, thereby enhancing the body's ability to eliminate tumor cells and potentially improving patient outcomes. In summary, LILRB1 protein plays a critical role in immune regulation and tumor immune evasion. It is of great significance for understanding the mechanisms of tumor immune escape, developing novel immunotherapeutic strategies, and evaluating patient prognosis, particularly in the context of immune checkpoint blockade therapies.


Version:4.0

SDS-PAGE



On SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA



Human LILRB1(ILT2) Protein; His Tag(Q8NHL6-1) (Catalog # GM-88549RP) was immobilized at 2 μ g/ml (100 μ L/well). Increasing concentrations of Anti-LILRB1(ILT2) mIgG1 Antibody (12D12) (Catalog # GM-27366AB) were added.